SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (Nasdaq: SABS) is a clinical-stage biopharmaceutical company developing human polyclonal antibody therapeutics through a proprietary platform based on genetically engineered cattle. The company went public following a business combination with Big Rock Partners Acquisition Corp., a blank-check vehicle sponsored by Big Rock Partners LLC that completed its IPO in 2020. The merger closed in late 2021, and the S-1 registration statement filed in August 2022 represents a post-combination securities registration as SABS continues to advance its pipeline. The company operates in the biotechnology sector, with programs targeting autoimmune and infectious disease indications. Sign up on SpacDesk for full filing history, deal data, and analytics on SABS and the broader SPAC universe.